Table 3.

Ongoing clinical trials in FGFR3-related skeletal dysplasias

Disorder	NCT number	Phase	Drug	Age of participants
Achondroplasia	4554940	II	Vosoritide	Up to 12 months (child)
	4085523	II	TransCon CNP	2–10 years (child)
	5246033	II	TransCon CNP	2–10 years (child)
	4638153	II	Recifercept	3 months to 10 years (child)
	5116046	II	Recifercept	15 months to 12 years (child)
	4265651	II	Infigratinib	3–11 years (child)
	5145010	II	Infigratinib	3–18 years (child, adult)
Hypochondroplasia	4219007	II	Vosoritide	3–10 years (child)

The National Clinical Trial (NCT) numbers denote ClinicalTrial.gov identifiers.

CNP, C-type natriuretic peptide.